Breaking News

TxCell Selects Lonza as CAR-Treg Cellular Product Manufacturer

Lonza will manufacture clinical batches of HLA-A2 CAR-Treg from its production site in Geleen

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

TxCell SA and Lonza Pharma & Biotech have entered into a Master Service Agreement for the manufacture of TxCell’s HLA-A2 CAR-Treg cellular product (TX200), which is in development for the prevention of chronic rejection after organ transplantation.   TxCell recently finalized its CAR-Treg manufacturing process and the transfer to Lonza began in February 2018. According to Lonza’s timeline, completion of transfer activities and start of clinical manufacturing is now expected by 1Q19. Accord...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters